-
hHEPATO-Cy5, a Bimodal Tracer for Image-Guided Hepatobiliary Surgery J Nucl. Med. (IF 9.1) Pub Date : 2024-07-18 Daphne D.D. Rietbergen, Tessa Buckle, Leon J. Slof, Maarten P. van Meerbeek, Clarize M. de Korne, Mick M. Welling, Matthias N. van Oosterom, Kevin Bauwens, Meta Roestenberg, Julia Kloetzl, Fijs W.B. van Leeuwen
Liver cancer is a leading cause of cancer deaths worldwide. Surgical resection of superficial hepatic lesions is increasingly guided by the disrupted bile excretion of the fluorescent dye indocyanine green (ICG). To extend this approach to deeper lesions, a dedicated bimodal tracer that facilitates both fluorescence guidance and radioguidance was developed. Methods: A tracer comprising a methylated
-
StepBrain: A 3-Dimensionally Printed Multicompartmental Anthropomorphic Brain Phantom to Simulate PET Activity Distributions J Nucl. Med. (IF 9.1) Pub Date : 2024-07-18 Maria Agnese Pirozzi, Valeria Gaudieri, Anna Prinster, Mario Magliulo, Alberto Cuocolo, Arturo Brunetti, Bruno Alfano, Mario Quarantelli
Visual Abstract
-
61Cu-PSMA–Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging J Nucl. Med. (IF 9.1) Pub Date : 2024-07-18 Tais Basaco Bernabeu, Rosalba Mansi, Luigi Del Pozzo, Sandra Zanger, Raghuvir H. Gaonkar, Lisa McDougall, Francesco De Rose, Leila Jaafar-Thiel, Michael Herz, Matthias Eiber, Gary A. Ulaner, Wolfgang A. Weber, Melpomeni Fani
Visual Abstract
-
Effectiveness and Patient Experiences of Rhenium Skin Cancer Therapy for Nonmelanoma Skin Cancer: Interim Results from the EPIC-Skin Study J Nucl. Med. (IF 9.1) Pub Date : 2024-07-18 Siddhartha Baxi, Saima Vohra, Angela Hong, Nicola Mulholland, Martin Heuschkel, Gerhard Dahlhoff, Giuseppe Cardaci, Siroos Mirzaei
Visual Abstract
-
211At-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation J Nucl. Med. (IF 9.1) Pub Date : 2024-07-18 Sofia H.L. Frost, Johnnie J. Orozco, Tom A. Bäck, Brian W. Miller, Erlinda B. Santos, Aimee Kenoyer, Sue E. Knoblaugh, Donald K. Hamlin, D. Scott Wilbur, Brenda M. Sandmaier
The α-emitter 211At deposits a high amount of energy within a few cell diameters, resulting in irreparable DNA double-strand breaks while minimizing off-target toxicity. We investigated the use of the 211At-labeled anti-CD45 monoclonal antibody (mAb) 211At-CD45-B10 as a nonmyeloablative conditioning regimen for dog-leukocyte-antigen–haploidentical hematopoietic cell transplantation. Methods: Seventeen
-
Paraplegic Patient with Metastatic Papillary Thyroid Cancer: A Multidisciplinary Approach to Radioactive Iodine Therapy Safety and Efficacy Strategy J Nucl. Med. (IF 9.1) Pub Date : 2024-07-11 Ghadah Al-Naqeeb, Eric Munger, Amrita L. Ramanathan, Andrew Makarewicz, Noha Behairy, Padmasree Veraraghavan, Craig Cochran, Philip Bernaldez, Iman Clinton, Newbegin Devaraj, Korressa Lee, Teresa Fisher, Olumide Owoade, Roberto Maass-Moreno, Babak Saboury, Sriram Gubbi, Joanna Klubo-Gwiezdzinska
High-activity radioactive iodine (RAI) therapy for metastatic thyroid cancer (TC) requires isolation to minimize radiation exposure to third parties, thus posing challenges for patients needing hands-on care. There are limited data on the approach to high-activity RAI treatment in paraplegic patients. We report a state-of-the-art multidisciplinary approach to the management of bedbound patients, covering
-
Factors Associated with Myocardial Uptake on Oncologic Somatostatin PET Investigations and Differentiation from Myocardial Uptake of Acute Myocarditis J Nucl. Med. (IF 9.1) Pub Date : 2024-07-11 Thomas Larive, Caroline Boursier, Marine Claudin, Jeanne Varlot, Laura Filippetti, Olivier Huttin, Véronique Roch, Laetitia Imbert, Matthieu Doyen, Aurélien Lambert, Damien Mandry, Zohra Lamiral, Elodie Chevalier, Pierre-Yves Marie
Myocardial somatostatin PET uptake is observed not only in most patients with acute myocarditis (AM) but also in some oncology patients referred for routine somatostatin PET. This raises concerns about the specificity of somatostatin PET for detecting myocarditis. The current study aims to identify factors associated with the detection of myocardial uptake on somatostatin PET scans recorded for oncology
-
Spleen Volume Reduction Is a Reliable and Independent Biomarker for Long-Term Risk of Leukopenia Development in Peptide Receptor Radionuclide Therapy J Nucl. Med. (IF 9.1) Pub Date : 2024-07-11 Lisa Steinhelfer, Friederike Jungmann, Lukas Endrös, Patrick Wenzel, Bernhard Haller, Manuel Nickel, Eva Haneder, Fabian Geisler, Katharina Götze, Alexander von Werder, Matthias Eiber, Markus R. Makowski, Rickmer Braren, Fabian Lohöfer
177Lu-DOTATATE therapy is an effective treatment for advanced neuroendocrine tumors, despite its dose-limiting hematotoxicity. Herein, the significance of off-target splenic irradiation is unknown. Our study aims to identify predictive markers of peptide receptor radionuclide therapy–induced leukopenia. Methods: We retrospectively analyzed blood counts and imaging data of 88 patients with histologically
-
Diagnostic Performance of 18F-FDG PET/CT According to Delay After Treatment to Detect Subclinical Recurrence of Head and Neck Squamous Cell Carcinoma J Nucl. Med. (IF 9.1) Pub Date : 2024-07-11 Camille Clement, Jean-Christophe Leclère, Clémentine Maheo, Romain Le Pennec, Gregoire Le Gal, Olivier Delcroix, Philippe Robin, Jean Rousset, Valentin Tissot, Aziliz Gueguen, Maryne Allio, Vincent Bourbonne, Ulrike Schick, Remi Marianowski, Pierre-Yves Salaun, Ronan Abgral
Head and neck squamous cell carcinoma (HNSCC) remains a malignancy with high rates of locoregional recurrence and poor prognosis for recurrent cases. Early detection of subclinical lesions is challenging but critical for effective patient management. Imaging surveillance after treatment, particularly 18F-FDG PET/CT, has shown promise in the diagnosis of HNSCC recurrence. The aim was to evaluate the
-
Elevated Baseline Mean Corpuscular Volume Predicts the Development of Severe Hematologic Toxicity After 177Lu-DOTATATE Therapy J Nucl. Med. (IF 9.1) Pub Date : 2024-07-11 Andrew F. Voter, Andrei Gafita, Rudolf A. Werner, Ana De Jesus-Acosta, Steven P. Rowe, Lilja B. Solnes
177Lu-DOTATATE is an effective second-line treatment for metastatic or nonresectable neuroendocrine tumors. This treatment can result in hematologic severe adverse reactions (SARs). Preemptive identification of patients at risk of SARs could mitigate this risk and improve treatment safety and outcomes. Methods: Demographic and oncologic history, pretreatment laboratory values, and SAR frequency were
-
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T J Nucl. Med. (IF 9.1) Pub Date : 2024-07-11 James P. Buteau, Louise Kostos, Ramin Alipour, Price Jackson, Lachlan McInstosh, Brittany Emmerson, Mohammad B. Haskali, Jing Xie, Elizabeth Medhurst, Rajeev Ravi, Brian D. Gonzalez, Heidi Fettke, Benjamin Blyth, Luc Furic, Katie Owen, Shahneen Sandhu, Declan G. Murphy, Arun A. Azad, Michael S. Hofman
[177Lu]Lu-PSMA is an effective class of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC); however, progression is inevitable. The limited durability of response may be partially explained by the presence of micrometastatic deposits, which are energy-sheltered and receive low absorbed radiation with 177Lu due to the approximately 0.7-mm mean pathlength. 161Tb has abundant
-
Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System J Nucl. Med. (IF 9.1) Pub Date : 2024-07-11 Fei Kang, Zhaojuan Xie, Wenhui Ma, Zhiyong Quan, Guiyu Li, Kun Guo, Xiang Li, Taoqi Ma, Weidong Yang, Yizhang Zhao, Hongyuan Yi, Yumo Zhao, Yihuan Lu, Jing Wang
Visual Abstract
-
The Rise of Molecular Image–Guided Robotic Surgery J Nucl. Med. (IF 9.1) Pub Date : 2024-07-11 Fijs W.B. van Leeuwen, Tessa Buckle, Matthias N. van Oosterom, Daphne D.D. Rietbergen
Following early acceptance by urologists, the use of surgical robotic platforms is rapidly spreading to other surgical fields. This empowerment of surgical perception via robotic advances occurs in parallel to developments in intraoperative molecular imaging. Convergence of these efforts creates a logical incentive to advance the decades-old image-guided robotics paradigm. This yields new radioguided
-
Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [177Lu]Lu-PSMA-I&T Therapy J Nucl. Med. (IF 9.1) Pub Date : 2024-07-03 Sandra Resch, Sibylle I. Ziegler, Gabriel Sheikh, Lena M. Unterrainer, Mathias J. Zacherl, Peter Bartenstein, Guido Böning, Julia Brosch-Lenz, Astrid Delker
Visual Abstract
-
Noninvasive Diagnostic Method to Objectively Measure Olfaction and Diagnose Smell Disorders by a Molecularly Targeted Fluorescence Imaging Agent J Nucl. Med. (IF 9.1) Pub Date : 2024-07-03 Dauren Adilbay, Junior Gonzales, Marianna Zazhytska, Paula Demetrio de Souza Franca, Sheryl Roberts, Tara D. Viray, Raik Artschwager, Snehal Patel, Albana Kodra, Jonathan B. Overdevest, Chun Yuen Chow, Glenn F. King, Sanjay K. Jain, Alvaro A. Ordonez, Laurence S. Carroll, Stavros Lomvardas, Thomas Reiner, Nagavarakishore Pillarsetty
Visual Abstract
-
An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 3: Contribution from Calculating Absorbed Dose from Time-Integrated Activity J Nucl. Med. (IF 9.1) Pub Date : 2024-07-03 Julia Brosch-Lenz, Sara Kurkowska, Eric Frey, Yuni K. Dewaraja, John Sunderland, Carlos Uribe
Visual Abstract
-
Performing [18F]MFBG Long–Axial-Field-of-View PET/CT Without Sedation or General Anesthesia for Imaging of Children with Neuroblastoma J Nucl. Med. (IF 9.1) Pub Date : 2024-07-03 Lise Borgwardt, Jesper Brok, Kim Francis Andersen, Jacob Madsen, Nicholas Gillings, Marie Øbro Fosbøl, Charlotte Lund Denholt, Ida Nymann Petersen, Louise Sørup Sørensen, Lotte Hahn Enevoldsen, Peter Sandor Oturai, Helle Hjort Johannesen, Liselotte Højgaard, Christina Schulze, Eunice Saxtoft, Flemming Andersen, Barbara Malene Fischer
Visual Abstract
-
The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue, 68Ga-FAPI-46 PET Data, and Survival Data J Nucl. Med. (IF 9.1) Pub Date : 2024-07-03 Christoph Oster, Lukas Kessler, Tobias Blau, Kathy Keyvani, Kim M. Pabst, Wolfgang P. Fendler, Pedro Fragoso Costa, Lazaros Lazaridis, Teresa Schmidt, Jonas Feldheim, Daniela Pierscianek, Hans Ulrich Schildhaus, Ulrich Sure, Yahya Ahmadipour, Christoph Kleinschnitz, Nika Guberina, Martin Stuschke, Cornelius Deuschl, Björn Scheffler, Ken Herrmann, Sied Kebir, Martin Glas
Despite their unique histologic features, gliosarcomas belong to the group of glioblastomas and are treated according to the same standards. Fibroblast activation protein (FAP) is a component of a tumor-specific subpopulation of fibroblasts that plays a critical role in tumor growth and invasion. Some case studies suggest an elevated expression of FAP in glioblastoma and a particularly strong expression
-
PET/CT-Based Absorbed Dose Maps in 90Y Selective Internal Radiation Therapy Correlate with Spatial Changes in Liver Function Derived from Dynamic MRI J Nucl. Med. (IF 9.1) Pub Date : 2024-07-03 Zhonglin Lu, Daniel F. Polan, Lise Wei, Madhava P. Aryal, Kellen Fitzpatrick, Chang Wang, Kyle C. Cuneo, Joseph R. Evans, Molly E. Roseland, Joseph J. Gemmete, Jared A. Christensen, Baljendra S. Kapoor, Justin K. Mikell, Yue Cao, Greta S.P. Mok, Yuni K. Dewaraja
Functional liver parenchyma can be damaged from treatment of liver malignancies with 90Y selective internal radiation therapy (SIRT). Evaluating functional parenchymal changes and developing an absorbed dose (AD)–toxicity model can assist the clinical management of patients receiving SIRT. We aimed to determine whether there is a correlation between 90Y PET AD voxel maps and spatial changes in the
-
Fibroblast Activation Protein–Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial J Nucl. Med. (IF 9.1) Pub Date : 2024-07-03 Lukas Kessler, Felix Schwaning, Martin Metzenmacher, Kim Pabst, Jens Siveke, Marija Trajkovic-Arsic, Benedikt Schaarschmidt, Marcel Wiesweg, Clemens Aigner, Till Plönes, Kaid Darwiche, Servet Bölükbas, Martin Stuschke, Lale Umutlu, Michael Nader, Dirk Theegarten, Rainer Hamacher, Wilfried E.E. Eberhardt, Martin Schuler, Ken Herrmann, Wolfgang P. Fendler, Hubertus Hautzel
The fibroblast activation protein (FAP) is highly expressed in tumor and stromal cells of mesothelioma and thus is an interesting imaging and therapeutic target. Previous data on PET imaging with radiolabeled FAP inhibitors (FAPIs) suggest high potential for superior tumor detection. Here, we report the data of a large malignant pleural mesothelioma cohort within a 68Ga-FAPI46 PET observational trial
-
Dosimetry of [177Lu]Lu-PSMA–Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis J Nucl. Med. (IF 9.1) Pub Date : 2024-07-03 Zachary Ells, Tristan R. Grogan, Johannes Czernin, Magnus Dahlbom, Jeremie Calais
Novel theranostic approaches using radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have emerged for treating metastatic castration-resistant prostate cancer. The physical properties and commercial availability of 177Lu make it one of the most used radionuclides for radiopharmaceutical therapy (RPT). In this literature review, we aimed at comparing the dosimetry of the most
-
Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Esther M.M. Smeets, Marija Trajkovic-Arsic, Daan Geijs, Sinan Karakaya, Monica van Zanten, Lodewijk A.A. Brosens, Benedikt Feuerecker, Martin Gotthardt, Jens T. Siveke, Rickmer Braren, Francesco Ciompi, Erik H.J.G. Aarntzen
Radiomics features can reveal hidden patterns in a tumor but usually lack an underlying biologic rationale. In this work, we aimed to investigate whether there is a correlation between radiomics features extracted from [18F]FDG PET images and histologic expression patterns of a glycolytic marker, monocarboxylate transporter-4 (MCT4), in pancreatic cancer. Methods: A cohort of pancreatic ductal adenocarcinoma
-
Deep Learning–Enabled Quantification of 99mTc-Pyrophosphate SPECT/CT for Cardiac Amyloidosis J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Robert J.H. Miller, Aakash Shanbhag, Anna M. Michalowska, Paul Kavanagh, Joanna X. Liang, Valerie Builoff, Nowell M. Fine, Damini Dey, Daniel S. Berman, Piotr J. Slomka
Transthyretin cardiac amyloidosis (ATTR CA) is increasingly recognized as a cause of heart failure in older patients, with 99mTc-pyrophosphate imaging frequently used to establish the diagnosis. Visual interpretation of SPECT images is the gold standard for interpretation but is inherently subjective. Manual quantitation of SPECT myocardial 99mTc-pyrophosphate activity is time-consuming and not performed
-
Granzyme B PET Imaging for Assessment of Disease Activity in Inflammatory Bowel Disease J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Pedram Heidari, Arvin Haj-Mirzaian, Suma Prabhu, Bahar Ataeinia, Shadi A. Esfahani, Umar Mahmood
Developing a noninvasive imaging method to detect immune system activation with a high temporal resolution is key to improving inflammatory bowel disease (IBD) management. In this study, granzyme B (GZMB), typically released from cytotoxic T and natural killer cells, was targeted using PET with 68Ga-NOTA-GZP (where GZP is β-Ala–Gly–Gly–Ile–Glu–Phe–Asp–CHO) to detect early intestinal inflammation in
-
Cerebral 18F-FDG PET/CT Metabolism as Diagnostic Signature for Central Nervous System Toxicity After Immune Checkpoint Blockade Cancer Treatment J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Yifei Ma, Jiling Zeng, Fadian Ding, Yiwei Xu, Youlong Wang, Guanqing Zhong, Nianqi Liu, Yanqi Wang, Yiming Li, Shuqin Chen, Xiaolong Wei, Pengfei Zhu, Guangmin Jian, Yu Si Niu, Guangzhen Fu, Cantong Liu, Guiqiang Li, Xiaotong Zhou, Ao Zhang, Shangeng Weng
Our aim was to investigate probable biomarkers specific to immune-related central nervous system toxicity (CNST) in cancer patients treated with immune checkpoint inhibitors (ICI) by analysis of 18F-FDG PET/CT images. Methods: Cancer patients receiving ICI treatment were enrolled in a multicenter observational study that analyzed regional metabolic changes before and during CNST onset from January
-
Patterns of Early Neocortical Amyloid-β Accumulation: A PET Population-Based Study J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Emily E. Lecy, Hoon-Ki Min, Christopher J. Apgar, Daniela D. Maltais, Emily S. Lundt, Sabrina M. Albertson, Matthew L. Senjem, Christopher G. Schwarz, Hugo Botha, Jonathan Graff-Radford, David T. Jones, Prashanthi Vemuri, Kejal Kantarci, David S. Knopman, Ronald C. Petersen, Clifford R. Jack, Jeyeon Lee, Val J. Lowe
The widespread deposition of amyloid-β (Aβ) plaques in late-stage Alzheimer disease is well defined and confirmed by in vivo PET. However, there are discrepancies between which regions contribute to the earliest topographic Aβ deposition within the neocortex. Methods: This study investigated Aβ signals in the perithreshold SUV ratio range using Pittsburgh compound B (PiB) PET in a population-based
-
Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [15O]H2O PET Imaging J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Roel Hoek, Pepijn A. van Diemen, Pieter G. Raijmakers, Roel S. Driessen, Yvemarie B.O. Somsen, Ruben W. de Winter, Ruurt A. Jukema, Jos W.R. Twisk, Lourens F.H.J. Robbers, Pim van der Harst, Antti Saraste, Mark Lubberink, Jens Sörensen, Paul Knaapen, Juhani Knuuti, Ibrahim Danad
Currently, cutoffs of quantitative [15O]H2O PET to detect fractional flow reserve (FFR)–defined coronary artery disease (CAD) were derived from a single cohort that included patients without prior CAD. However, prior CAD, sex, and age can influence myocardial blood flow (MBF). Therefore, the present study determined the influence of prior CAD, sex, and age on optimal cutoffs of hyperemic MBF (hMBF)
-
Natural History of Myocardial αvβ3 Integrin Expression After Acute Myocardial Infarction: Correlation with Changes in Myocardial Blood Flow J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Matthieu Dietz, Christel H. Kamani, Colin Bousige, Vincent Dunet, Judith Delage, Vladimir Rubimbura, Marie Nicod Lalonde, Giorgio Treglia, Niklaus Schaefer, Wail Nammas, Antti Saraste, Juhani Knuuti, Nathan Mewton, John O. Prior
Angiogenesis is an essential part of the cardiac repair process after myocardial infarction, but its spatiotemporal dynamics remain to be fully deciphered.68Ga-NODAGA-Arg-Gly-Asp (RGD) is a PET tracer targeting αvβ3 integrin expression, which is a marker of angiogenesis. Methods: In this prospective single-center trial, we aimed to monitor angiogenesis through myocardial integrin αvβ3 expression in
-
Dose Reduction in Pediatric Oncology Patients with Delayed Total-Body [18F]FDG PET/CT J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Clemens Mingels, Benjamin A. Spencer, Hande Nalbant, Negar Omidvari, Mehrad Rokni, Axel Rominger, Fatma Sen, Simon R. Cherry, Ramsey D. Badawi, Yasser G. Abdelhafez, Lorenzo Nardo
Our aim was to define a lower limit of reduced injected activity in delayed [18F]FDG total-body (TB) PET/CT in pediatric oncology patients. Methods: In this single-center prospective study, children were scanned for 20 min with TB PET/CT, 120 min after intravenous administration of a 4.07 ± 0.49 MBq/kg dose of [18F]FDG. Five randomly subsampled low-count reconstructions were generated using ¼, ⅛,
-
Safety and Efficacy of Radiosynoviorthesis: A Prospective Canadian Multicenter Study J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Mélanie Desaulniers, Michel Paquette, Stéphanie Dubreuil, Helena Senta, Éric Lavallée, J. Carter Thorne, Éric Turcotte
Radiosynoviorthesis is approved in several European countries and the United States to treat refractory synovitis in many inflammatory joint diseases, such as rheumatoid arthritis, spondyloarthropathies, and other arthritic joint diseases. No radiopharmaceuticals for radiosynoviorthesis are currently approved in Canada. The aim of this Health Canada–approved trial was to demonstrate the safety and
-
Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of 99mTc and 188Re Theranostic Agents for Prostate Cancer J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Truc T. Pham, Ingebjørg N. Hungnes, Charlotte Rivas, Julie Cleaver, George Firth, Philip J. Blower, Jane Sosabowski, Gary J.R. Cook, Lefteris Livieratos, Jennifer D. Young, Paul G. Pringle, Michelle T. Ma
Benchtop 99Mo/99mTc and 188W/188Re generators enable economical production of molecular theranostic 99mTc and 188Re radiopharmaceuticals, provided that simple, kit-based chemistry exists to radiolabel targeting vectors with these radionuclides. We have previously described a diphosphine platform that efficiently incorporates 99mTc into receptor-targeted peptides. Here, we report its application to
-
True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Mark T. Fleming, Rick Hermsen, Andrei S. Purysko, Albert Chau, Phillip Davis, Brian F. Chapin, David M. Schuster
18F-rhPSMA-7.3 (18F-flotufolastat) is a high-affinity prostate-specific membrane antigen–targeted diagnostic radiopharmaceutical for PET imaging in patients with prostate cancer. Here, we report findings from the SPOTLIGHT study (NCT04186845), assessing the performance of 18F-flotufolastat PET/CT for identifying prostate-specific membrane antigen–positive lesions confirmed by standard of truth (SoT)
-
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial) J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 John Nikitas, Ethan Lam, Kiara Adame Booker, Wolfgang P. Fendler, Matthias Eiber, Boris Hadaschik, Ken Herrmann, Nader Hirmas, Helena Lanzafame, Martin Stuschke, Johannes Czernin, Michael L. Steinberg, Nicholas G. Nickols, Amar U. Kishan, Jeremie Calais
This multicenter randomized phase III trial (NCT04457245) evaluated the effect of performing prostate-specific membrane antigen (PSMA) PET/CT before definitive radiotherapy. Methods: Men with unfavorable intermediate- or high-risk prostate cancer were randomized 1.08:1 between receiving and not receiving a PSMA PET/CT scan before definitive radiotherapy. All other imaging modalities were allowed in
-
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Carl Fredrik Warfvinge, Johan Gustafsson, Daniel Roth, Jan Tennvall, Johanna Svensson, Peter Bernhardt, Anna Åkesson, Elinore Wieslander, Anna Sundlöv, Katarina Sjögreen Gleisner
Peptide receptor radionuclide therapy presents the possibility of tracing and quantifying the uptake of the drug in the body and performing dosimetry, potentially allowing individualization of treatment schemes. However, the details of how neuroendocrine tumors (NETs) respond to different absorbed doses are insufficiently known. Here, we investigated the relationship between tumor-absorbed dose and
-
Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Surekha Yadav, Fei Jiang, Sara Kurkowska, Rachelle Saelee, Amanda Morley, Felix Feng, Rahul Aggarwal, Courtney Lawhn-Heath, Carlos Uribe, Thomas A. Hope
Understanding the relationship between lesion-absorbed dose and tumor response in 177Lu-PSMA-617 radiopharmaceutical therapies (RPTs) remains complex. We aimed to investigate whether baseline lesion-absorbed dose can predict lesion-based responses and to explore the connection between lesion-absorbed dose and prostate-specific antigen (PSA) response. Methods: In this retrospective study, we evaluated
-
Deescalated 225Ac-PSMA-617 Versus 177Lu/225Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Hendrik Rathke, Erik Winter, Frank Bruchertseifer, Manuel Röhrich, Frederik Lars Giesel, Uwe Haberkorn, Alfred Morgenstern, Clemens Kratochwil
The aim of this work is to evaluate our clinical real-world data obtained with 225Ac-PSMA-617 (AcPSMA), which were acquired under compassionate care regulations in patients with advanced-stage prostate cancer. The objective parameters that could be derived from this evaluation are compared with previous literature about AcPSMA and 177Lu-PSMA-617 (LuPSMA). Methods: The medical files of all patients
-
A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Neeta Pandit-Taskar, Joseph A. O’Donoghue, Dushen Chetty, Steven Max, Danielle Wanik, Ohad Ilovich, Michael Russell, Tenzin Nyima, Chaitanya R. Divgi, Margaret Yu, Michael J. Morris
Despite the inclusion of multiple agents within the prostate cancer treatment landscape, new treatment options are needed to address the unmet need for patients with metastatic castration-resistant prostate cancer (mCRPC). Although prostate-specific membrane antigen is the only cell-surface target to yield clinical benefit in men with advanced prostate cancer, additional targets may further advance
-
CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Cinzia Imberti, Roberto De Gregorio, Joshua A. Korsen, Tran T. Hoang, Samantha Khitrov, Teja Kalidindi, Subhiksha Nandakumar, Jooyoung Park, Samir Zaidi, Naga Vara Kishore Pillarsetty, Jason S. Lewis
The incidence of androgen receptor (AR)–negative (AR−) prostate cancer, including aggressive neuroendocrine prostate cancer (NEPC), has more than doubled in the last decade, but its timely diagnosis is difficult as it lacks typical prostate cancer hallmarks. The carcinoembryonic antigen–related cell adhesion molecule 5 (CEACAM5) has recently been identified as an upregulated surface antigen in NEPC
-
In Vivo PET Imaging of 89Zr-Labeled Natural Killer Cells and the Modulating Effects of a Therapeutic Antibody J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Truc T. Pham, Alicia Chenoweth, Natasha Patel, Arshiya Banu, Gabriel Osborn, Philip J. Blower, Sophia N. Karagiannis, Michelle T. Ma
Natural killer (NK) cells can kill cancer cells via antibody-dependent cell-mediated cytotoxicity (ADCC): a tumor-associated IgG antibody binds to the Fc receptor CD16 on NK cells via the antibody Fc region and activates the cytotoxic functions of the NK cell. Here, we used PET imaging to assess NK cell migration to human epidermal growth factor receptor 2 (HER2)–positive HCC1954 breast tumors, examining
-
Prognostic Implications of 68Ga-FAPI-46 PET/CT–Derived Parameters on Overall Survival in Various Types of Solid Tumors J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Masao Watanabe, Wolfgang P. Fendler, Hong Grafe, Nader Hirmas, Rainer Hamacher, Helena Lanzafame, Kim M. Pabst, Hubertus Hautzel, Clemens Aigner, Stefan Kasper, Bastian von Tresckow, Martin Stuschke, Sherko Kümmel, Celine Lugnier, Boris Hadaschik, Viktor Grünwald, Fadi Zarrad, Jens T. Siveke, Ken Herrmann, Manuel Weber
Tumoral fibroblast activation protein expression is associated with proliferation and angiogenesis and can be visualized by PET/CT. We examined the prognostic value of [68Ga]Ga-fibroblast activation protein inhibitor (FAPI) (68Ga-FAPI)–46 PET/CT for different tumor entities in patients enrolled in 2 prospective imaging studies (NCT05160051, n = 30; NCT04571086, n = 115). Methods: Within 4 wk, 145 patients
-
Diagnostic Performance of [18F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Jie Zang, Yun Yang, Shaoming Chen, Chao Wang, Shaohao Chen, Shun Hu, Hai Cai, Xiaodong Li, Ning Xu, Xiaoyuan Chen, Jingjing Zhang, Weibing Miao
This study aimed to assess the diagnostic value of [18F]AlF-thretide PET/CT in patients with newly diagnosed prostate cancer (PCa). Methods: In total, 49 patients with biopsy-proven PCa were enrolled in this prospective study. All patients underwent [18F]AlF-thretide PET/CT, and the scoring system of the PRIMARY trial was used for PET image analysis. The dosimetry evaluation of [18F]AlF-thretide was
-
A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Laura Evangelista, Fabio Zattoni, Marta Burei, Daniele Bertin, Eugenio Borsatti, Tanja Baresic, Mohsen Farsad, Emanuela Trenti, Mirco Bartolomei, Stefano Panareo, Luca Urso, Giuseppe Trifirò, Elisabetta Brugola, Franca Chierichetti, Davide Donner, Lucia Setti, Mauro Gallan, Paola Del Bianco, Giovanna Magni, Gian Luca De Salvo, Giacomo Novara, the Study Group Coinvestigators
This study aimed to compare the efficacy of [18F]F-choline PET/CT with conventional imaging for staging and managing intermediate- to high-risk prostate cancer (PCa). The primary objective was to assess the ability of PET/CT with [18F]F-choline to identify lymph node and systemic involvement during initial staging. Secondary objectives included evaluating the impact of [18F]F-choline PET/CT on unnecessary
-
Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Moe S. Sadaghiani, Saradha Baskaran, Michael A. Gorin, Steven P. Rowe, Jean-Claude Provost, Iryna Teslenko, Roman Bilyk, Hong An, Sara Sheikhbahaei
Prostate-specific membrane antigen (PSMA) is expressed in the neovasculature of multiple solid tumors, including renal cell carcinoma (RCC). Studies have demonstrated promising results on the utility of PSMA-targeted PET/CT imaging in RCC. This report aims to provide a systematic review and metaanalysis on the utility and detection rate of PSMA PET/CT imaging in staging or evaluation of primary RCC
-
Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Wenhui Zhou, Sumit Halder, Sanna Herwald, Michael Ghijsen, Gowhar Shafi, Mohan Uttarwar, Eric Rosen, Benjamin Franc, Sirish Kishore
Prostate-specific membrane antigen (PSMA) is frequently overexpressed in nonprostate malignancies. This preclinical study investigated the molecular basis of the application of PMSA-targeting radiopharmaceuticals in breast cancer subtypes. Methods: The somatic copy number status and the transcriptomic and protein expressions of FOLH1 (gene name of PSMA) were analyzed across breast cancer subtypes in
-
Molecular Imaging in Gynecology: Beyond Cancer J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Joni Sebastiano, Cindy Rodriguez, Zachary V. Samuels, Kristen Pepin, Brian M. Zeglis
Gynecological pathologies account for approximately 4.5% of the overall global disease burden. Although cancers of the female reproductive system have understandably been the focus of a great deal of research, benign gynecological conditions—such as endometriosis, polycystic ovary syndrome, and uterine fibroids—have remained stubbornly understudied despite their astonishing ubiquity and grave morbidity
-
Is Automatic Tumor Segmentation on Whole-Body 18F-FDG PET Images a Clinical Reality? J Nucl. Med. (IF 9.1) Pub Date : 2024-07-01 Lalith Kumar Shiyam Sundar, Thomas Beyer
The integration of automated whole-body tumor segmentation using 18F-FDG PET/CT images represents a pivotal shift in oncologic diagnostics, enhancing the precision and efficiency of tumor burden assessment. This editorial examines the transition toward automation, propelled by advancements in artificial intelligence, notably through deep learning techniques. We highlight the current availability of
-
Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression J Nucl. Med. (IF 9.1) Pub Date : 2024-06-27 Duminduni Hewa Angappulige, Nimrod S. Barashi, Nicholas Pickersgill, Cody Weimholt, Jingqin Luo, Ghazal Shadmani, Ziad Tarcha, Sampanna Rayamajhi, Nupam P. Mahajan, Gerald L. Andriole, Barry A. Siegel, Eric H. Kim, Kiran Mahajan
Visual Abstract
-
Prognostic Value of 18F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE J Nucl. Med. (IF 9.1) Pub Date : 2024-06-27 Virginie Combet-Curt, Chloé Buchalet, Karine Le Malicot, Claire Lemanski, Emmanuel Deshayes, Nathalie Bonichon-Lamichhane, Astrid Lièvre, Florence Huguet, Ghoufrane Tlili, Véronique Vendrely
This study aimed to evaluate the prognostic value of 18F-FDG PET/CT qualitative assessment in terms of recurrence-free survival (RFS), colostomy-free survival (CFS), and overall survival (OS) after radiation therapy (RT) of squamous cell carcinoma of the anus (SCCA). Secondary objectives were to evaluate the prognostic value of baseline and posttherapeutic quantitative 18F-FDG PET/CT parameters in
-
Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study) J Nucl. Med. (IF 9.1) Pub Date : 2024-06-27 Matteo Bauckneht, Francesco Lanfranchi, Domenico Albano, Luca Triggiani, Flavia Linguanti, Luca Urso, Rosario Mazzola, Alessio Rizzo, Elisa D’Angelo, Francesco Dondi, Eneida Mataj, Gloria Pedersoli, Elisabetta Maria Abenavoli, Luca Vaggelli, Beatrice Detti, Naima Ortolan, Antonio Malorgio, Alessia Guarneri, Federico Garrou, Matilde Fiorini, Serena Grimaldi, Pietro Ghedini, Giuseppe Carlo Iorio, Antonella
Visual Abstract
-
Dose–Response Relationship in Patients with Liver Metastases from Neuroendocrine Neoplasms Undergoing Radioembolization with 90Y Glass Microspheres J Nucl. Med. (IF 9.1) Pub Date : 2024-06-21 Masao Watanabe, Stephan Leyser, Jens Theysohn, Benedikt Schaarschmidt, Johannes Ludwig, Wolfgang P. Fendler, Alexandros Moraitis, Harald Lahner, Annie Mathew, Ken Herrmann, Manuel Weber
The benefit of multicompartment dosimetry in the radioembolization of neuroendocrine neoplasms is not firmly established. We retrospectively assessed its potential with patient outcome. Methods: Forty-three patients were eligible. The association of mean absorbed dose (MAD) for tumors and treatment response was tested per lesion with a receiver operating characteristic curve analysis, and the association
-
Facilitating the End of the Linear No-Threshold Model Era J Nucl. Med. (IF 9.1) Pub Date : 2024-06-21 Mohan Doss
The linear no-threshold (LNT) model, which asserts that any level of ionizing radiation increases cancer risk, has been the basis of global radiation protection policies since the 1950s. Despite ongoing endorsements, a growing body of evidence challenges the LNT model, suggesting instead that low-level radiation exposure might reduce cancer risk, a concept known as radiation hormesis. This editorial
-
RadShap: An Explanation Tool for Highlighting the Contributions of Multiple Regions of Interest to the Prediction of Radiomic Models J Nucl. Med. (IF 9.1) Pub Date : 2024-06-21 Nicolas Captier, Fanny Orlhac, Narinée Hovhannisyan-Baghdasarian, Marie Luporsi, Nicolas Girard, Irène Buvat
Visual Abstract
-
Interreader and Intrareader Reproducibility of 18F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies J Nucl. Med. (IF 9.1) Pub Date : 2024-06-13 Phillip H. Kuo, Giuseppe Esposito, Gary A. Ulaner, Don Yoo, Katherine Zukotynski, Gregory C. Ravizzini, Ross Penny, Matthew P. Miller, Albert Chau, Phillip Davis, Brian F. Chapin, David M. Schuster, on behalf of the SPOTLIGHT and LIGHTHOUSE study groups
Visual Abstract
-
Synthesis of 64Cu-, 55Co-, and 68Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles J Nucl. Med. (IF 9.1) Pub Date : 2024-06-13 German O. Fonseca Cabrera, Xinrui Ma, Wilson Lin, Tao Zhang, Weiling Zhao, Liqin Pan, Xiaomei Li, Todd E. Barnhart, Eduardo Aluicio-Sarduy, Huaifu Deng, Xuedan Wu, Kadalipura P. Rakesh, Zibo Li, Jonathan W. Engle, Zhanhong Wu
The development of theranostic radiotracers relies on their binding to specific molecular markers of a particular disease and the use of corresponding radiopharmaceutical pairs thereafter. This study reports the use of multiamine macrocyclic moieties (MAs), as linkers or chelators, in tracers targeting the neurotensin receptor-1 (NTSR-1). The goal is to achieve elevated tumor uptake, minimal background
-
Design of a Fibroblast Activation Protein–Targeted Radiopharmaceutical Therapy with High Tumor–to–Healthy-Tissue Ratios J Nucl. Med. (IF 9.1) Pub Date : 2024-06-13 Ramesh Mukkamala, Daniel J. Carlson, Nicholas Kaine Miller, Spencer D. Lindeman, Emily Renee Bowen, Pooja Tudi, Taylor Schleinkofer, Owen C. Booth, Abigail Cox, Madduri Srinivasarao, Philip S. Low
Because of upregulated expression on cancer-associated fibroblasts, fibroblast activation protein (FAP) has emerged as an attractive biomarker for the imaging and therapy of solid tumors. Although many FAP ligands have already been developed for radiopharmaceutical therapies (RPTs), most suffer from inadequate tumor uptake, insufficient tumor residence times, or off-target accumulation in healthy tissues
-
Performance Characteristics of the NeuroEXPLORER, a Next-Generation Human Brain PET/CT Imager J Nucl. Med. (IF 9.1) Pub Date : 2024-06-13 Hongdi Li, Ramsey D. Badawi, Simon R. Cherry, Kathryn Fontaine, Liuchun He, Shannan Henry, Ansel T. Hillmer, Lingzhi Hu, Nikkita Khattar, Edwin K. Leung, Tiantian Li, Yusheng Li, Chi Liu, Peng Liu, Zhenrui Lu, Stanislaw Majewski, David Matuskey, Evan D. Morris, Tim Mulnix, Negar Omidvari, Suranjana Samanta, Aaron Selfridge, Xishan Sun, Takuya Toyonaga, Tommaso Volpi, Tianyi Zeng, Terry Jones, Jinyi
Visual Abstract
-
A Deep-Learning–Based Partial-Volume Correction Method for Quantitative 177Lu SPECT/CT Imaging J Nucl. Med. (IF 9.1) Pub Date : 2024-06-01 Julian Leube, Johan Gustafsson, Michael Lassmann, Maikol Salas-Ramirez, Johannes Tran-Gia
With the development of new radiopharmaceutical therapies, quantitative SPECT/CT has progressively emerged as a crucial tool for dosimetry. One major obstacle of SPECT is its poor resolution, which results in blurring of the activity distribution. Especially for small objects, this so-called partial-volume effect limits the accuracy of activity quantification. Numerous methods for partial-volume correction
-
Mapping 18F-FDG Kinetics Together with Patient-Specific Bootstrap Assessment of Uncertainties: An Illustration with Data from a PET/CT Scanner with a Long Axial Field of View J Nucl. Med. (IF 9.1) Pub Date : 2024-06-01 Qi Wu, Fengyun Gu, Liam D. O’Suilleabhain, Hasan Sari, Song Xue, Kuangyu Shi, Axel Rominger, Finbarr O’Sullivan
The purpose of this study was to examine a nonparametric approach to mapping kinetic parameters and their uncertainties with data from the emerging generation of dynamic whole-body PET/CT scanners. Methods: Dynamic PET 18F-FDG data from a set of 24 cancer patients studied on a long-axial-field-of-view PET/CT scanner were considered. Kinetics were mapped using a nonparametric residue mapping (NPRM)
-
Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in Locally Advanced Cervical Cancer? J Nucl. Med. (IF 9.1) Pub Date : 2024-06-01 Angela Collarino, Vanessa Feudo, Tina Pasciuto, Anita Florit, Elisabeth Pfaehler, Marco de Summa, Nicolò Bizzarri, Salvatore Annunziata, Gian Franco Zannoni, Lioe-Fee de Geus-Oei, Gabriella Ferrandina, Maria Antonietta Gambacorta, Giovanni Scambia, Ronald Boellaard, Evis Sala, Vittoria Rufini, Floris HP van Velden
This study investigated whether radiomic features extracted from pretreatment [18F]FDG PET could improve the prediction of both histopathologic tumor response and survival in patients with locally advanced cervical cancer (LACC) treated with neoadjuvant chemoradiotherapy followed by surgery compared with conventional PET parameters and histopathologic features. Methods: The medical records of all consecutive
-
PET Quantification of [18F]VAT in Human Brain and Its Test–Retest Reproducibility and Age Dependence J Nucl. Med. (IF 9.1) Pub Date : 2024-06-01 John L. O’Donnell, Anil Kumar Soda, Hao Jiang, Scott A. Norris, Baijayanta Maiti, Morvarid Karimi, Meghan C. Campbell, Stephen M. Moerlein, Zhude Tu, Joel S. Perlmutter
Molecular imaging of brain vesicular acetylcholine transporter provides a biomarker to explore cholinergic systems in humans. We aimed to characterize the distribution of, and optimize methods to quantify, the vesicular acetylcholine transporter–specific tracer (−)-(1-(8-(2-[18F]fluoroethoxy)-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-piperidin-4-yl)(4-fluorophenyl)methanone ([18F]VAT) in the brain